IN THE INTERESTS OF PATIENTS, ROCHE WILL CONSIDER ALL OPTIONS FOLLOWING CHMP OPINION ON TARCEVA IN PANCREATIC CANCER

Roche announced that its cancer medicine Tarceva (erlotinib) has received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) for use in combination with gemcitabine chemotherapy for the first line treatment of advanced pancreatic cancer, a cancer with an extremely high fatality rate. Roche is confident in the trial data which has shown that the Tarceva combination treatment significantly increases patient survival. In the interest of the patients, Roche will now consider all options following this decision, including requesting a re-examination of this decision.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/07-28-2006/0004405864&EDATE=)